Abstract
Premature ejaculation is generally regarded the most frequent male ejaculatory complaint and has been considered a psychosexual disorder with psychogenic aetiology. The efficacy of various antidepressants, however, to delay ejaculation in men and to pharmacologically treat premature ejaculation suggests a strong neurobiological involvement. Most of our current understanding of the neurobiology and neuroanatomy of sexual behavior and ejaculatory function has been derived from preclinical studies using several laboratory species. In the present paper we will review the various animal models that have been developed to further study ejaculatory function in the laboratory rat. In addition, we will briefly review the effects of serotonergic antidepressants and serotonergic compounds on sexual and ejaculatory behavior. Together, these preclinical studies may contribute to a better understanding of the neurobiology of ejaculation and help the development of novel drug targets to treat ejaculatory disorders such as premature ejaculation.
Keywords: Premature ejaculation, animal model, SSRI, serotonine
Current Pharmaceutical Design
Title: Animal Models of Ejaculatory Behavior
Volume: 11 Issue: 31
Author(s): T. Pattij, B. Olivier and M. D. Waldinger
Affiliation:
Keywords: Premature ejaculation, animal model, SSRI, serotonine
Abstract: Premature ejaculation is generally regarded the most frequent male ejaculatory complaint and has been considered a psychosexual disorder with psychogenic aetiology. The efficacy of various antidepressants, however, to delay ejaculation in men and to pharmacologically treat premature ejaculation suggests a strong neurobiological involvement. Most of our current understanding of the neurobiology and neuroanatomy of sexual behavior and ejaculatory function has been derived from preclinical studies using several laboratory species. In the present paper we will review the various animal models that have been developed to further study ejaculatory function in the laboratory rat. In addition, we will briefly review the effects of serotonergic antidepressants and serotonergic compounds on sexual and ejaculatory behavior. Together, these preclinical studies may contribute to a better understanding of the neurobiology of ejaculation and help the development of novel drug targets to treat ejaculatory disorders such as premature ejaculation.
Export Options
About this article
Cite this article as:
Pattij T., Olivier B. and Waldinger D. M., Animal Models of Ejaculatory Behavior, Current Pharmaceutical Design 2005; 11 (31) . https://dx.doi.org/10.2174/138161205774913363
DOI https://dx.doi.org/10.2174/138161205774913363 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Investigation on the Development of Losartan Potassium Sustained Release Microspheres by Solvent Evaporation Methods
Micro and Nanosystems LRP-Mediated Clearance of Aβ is Inhibited by KPI-Containing Isoforms of APP
Current Alzheimer Research Dementia and the Default Mode
Current Alzheimer Research Research Domain Criteria (RDoC): A Perspective to Probe the Biological Background behind Treatment Efficacy in Depression
Current Medicinal Chemistry Bupropion-SR for Smoking Reduction and Cessation in Alcohol-Dependent Outpatients: A Naturalistic, Open-Label Study
Current Clinical Pharmacology The Emerging Role of Melatonin Agonists in the Treatment of Major Depression: Focus on Agomelatine
CNS & Neurological Disorders - Drug Targets Acknowledgements to Reviewers
CNS & Neurological Disorders - Drug Targets Malignant Hypercalcemia
Current Medicinal Chemistry Editorial: Second International Conference on Novel Psychoactive Substances (NPSs): Keynote Addresses and Conference Abstracts
Current Drug Abuse Reviews Multiple Sclerosis: Current and Future Treatment Options
Endocrine, Metabolic & Immune Disorders - Drug Targets Modeling of Drug Released from Acyclovir Nanoparticles Based on Artificial Neural Networks
Letters in Drug Design & Discovery Nanoparticle Based Gene Therapy Approach: A Pioneering Rebellion in the Management of Psychiatric Disorders
Current Gene Therapy Food Selectivity, Gastrointestinal Symptoms and Urine Organic Acids in Autism Spectrum Disorder: A Pilot Study
Current Nutrition & Food Science Antioxidants as Potentially Safe Antidotes for Organophosphorus Poisoning
Current Enzyme Inhibition Glutamate Hypothesis of Schizophrenia and Approach for Possible Therapeutic Drugs
Current Medicinal Chemistry - Central Nervous System Agents Targeting the Akt-pathway to Improve Radiosensitivity in Glioblastoma
Current Pharmaceutical Design Members of CRF Family and their Receptors: From Past to Future
Current Medicinal Chemistry Epigenetic Modulation: A Promising Avenue to Advance Hematopoietic Stem Cell-Based Therapy for Severe Autoimmune Disorders
Epigenetic Diagnosis & Therapy (Discontinued) Review of PI3K/mTOR Inhibitors Entering Clinical Trials to Treat Triple Negative Breast Cancers
Recent Patents on Anti-Cancer Drug Discovery Analysis of Soybean Root Proteins Affected by Gibberellic Acid Treatment Under Flooding Stress
Protein & Peptide Letters